Global Liraglutide for The Treatment of Diabetes and Obesity Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Liraglutide is a medication approved for the treatment of both type 2 diabetes mellitus and obesity.It belongs to the class of glucagon-like peptide-1(GLP-1)receptor agonists,which can enhance glucose-dependent insulin secretion,suppress glucagon release,slow gastric emptying,and promote satiety,thereby improving glycemic control and potentially aiding in weight loss.
The global Liraglutide for The Treatment of Diabetes and Obesity market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Liraglutide for The Treatment of Diabetes and Obesity Industry Forecast” looks at past sales and reviews total world Liraglutide for The Treatment of Diabetes and Obesity sales in 2023, providing a comprehensive analysis by region and market sector of projected Liraglutide for The Treatment of Diabetes and Obesity sales for 2024 through 2030. With Liraglutide for The Treatment of Diabetes and Obesity sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liraglutide for The Treatment of Diabetes and Obesity industry.
This Insight Report provides a comprehensive analysis of the global Liraglutide for The Treatment of Diabetes and Obesity landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liraglutide for The Treatment of Diabetes and Obesity portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Liraglutide for The Treatment of Diabetes and Obesity market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liraglutide for The Treatment of Diabetes and Obesity and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liraglutide for The Treatment of Diabetes and Obesity.
United States market for Liraglutide for The Treatment of Diabetes and Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Liraglutide for The Treatment of Diabetes and Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Liraglutide for The Treatment of Diabetes and Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Liraglutide for The Treatment of Diabetes and Obesity players cover Novo Nordisk, Teva, Huadong Medicine, Sino Biopharm, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Liraglutide for The Treatment of Diabetes and Obesity market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Liraglutide for The Treatment of Diabetes and Obesity market?
What factors are driving Liraglutide for The Treatment of Diabetes and Obesity market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liraglutide for The Treatment of Diabetes and Obesity market opportunities vary by end market size?
How does Liraglutide for The Treatment of Diabetes and Obesity break out by Type, by Application?
Liraglutide is a medication approved for the treatment of both type 2 diabetes mellitus and obesity.It belongs to the class of glucagon-like peptide-1(GLP-1)receptor agonists,which can enhance glucose-dependent insulin secretion,suppress glucagon release,slow gastric emptying,and promote satiety,thereby improving glycemic control and potentially aiding in weight loss.
The global Liraglutide for The Treatment of Diabetes and Obesity market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Liraglutide for The Treatment of Diabetes and Obesity Industry Forecast” looks at past sales and reviews total world Liraglutide for The Treatment of Diabetes and Obesity sales in 2023, providing a comprehensive analysis by region and market sector of projected Liraglutide for The Treatment of Diabetes and Obesity sales for 2024 through 2030. With Liraglutide for The Treatment of Diabetes and Obesity sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liraglutide for The Treatment of Diabetes and Obesity industry.
This Insight Report provides a comprehensive analysis of the global Liraglutide for The Treatment of Diabetes and Obesity landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liraglutide for The Treatment of Diabetes and Obesity portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Liraglutide for The Treatment of Diabetes and Obesity market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liraglutide for The Treatment of Diabetes and Obesity and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liraglutide for The Treatment of Diabetes and Obesity.
United States market for Liraglutide for The Treatment of Diabetes and Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Liraglutide for The Treatment of Diabetes and Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Liraglutide for The Treatment of Diabetes and Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Liraglutide for The Treatment of Diabetes and Obesity players cover Novo Nordisk, Teva, Huadong Medicine, Sino Biopharm, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Liraglutide for The Treatment of Diabetes and Obesity market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Original Drug
- Generic Drug
- Hospital and Clinic
- Retail Pharmacies
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novo Nordisk
- Teva
- Huadong Medicine
- Sino Biopharm
What is the 10-year outlook for the global Liraglutide for The Treatment of Diabetes and Obesity market?
What factors are driving Liraglutide for The Treatment of Diabetes and Obesity market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liraglutide for The Treatment of Diabetes and Obesity market opportunities vary by end market size?
How does Liraglutide for The Treatment of Diabetes and Obesity break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Liraglutide for The Treatment of Diabetes and Obesity by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Liraglutide for The Treatment of Diabetes and Obesity by Country/Region, 2019, 2023 & 2030
2.2 Liraglutide for The Treatment of Diabetes and Obesity Segment by Type
2.2.1 Original Drug
2.2.2 Generic Drug
2.3 Liraglutide for The Treatment of Diabetes and Obesity Sales by Type
2.3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Type (2019-2024)
2.3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue and Market Share by Type (2019-2024)
2.3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Price by Type (2019-2024)
2.4 Liraglutide for The Treatment of Diabetes and Obesity Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Liraglutide for The Treatment of Diabetes and Obesity Sales by Application
2.5.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Market Share by Application (2019-2024)
2.5.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue and Market Share by Application (2019-2024)
2.5.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Breakdown Data by Company
3.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales by Company (2019-2024)
3.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Company (2019-2024)
3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue by Company (2019-2024)
3.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Company (2019-2024)
3.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Company (2019-2024)
3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Price by Company
3.4 Key Manufacturers Liraglutide for The Treatment of Diabetes and Obesity Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Liraglutide for The Treatment of Diabetes and Obesity Product Location Distribution
3.4.2 Players Liraglutide for The Treatment of Diabetes and Obesity Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LIRAGLUTIDE FOR THE TREATMENT OF DIABETES AND OBESITY BY GEOGRAPHIC REGION
4.1 World Historic Liraglutide for The Treatment of Diabetes and Obesity Market Size by Geographic Region (2019-2024)
4.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country/Region (2019-2024)
4.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales by Country/Region (2019-2024)
4.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue by Country/Region (2019-2024)
4.3 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales Growth
4.4 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales Growth
4.5 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Growth
4.6 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Growth
5 AMERICAS
5.1 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Country
5.1.1 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2019-2024)
5.1.2 Americas Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2019-2024)
5.2 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)
5.3 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Region
6.1.1 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2019-2024)
6.1.2 APAC Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region (2019-2024)
6.2 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)
6.3 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Liraglutide for The Treatment of Diabetes and Obesity by Country
7.1.1 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2019-2024)
7.1.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2019-2024)
7.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)
7.3 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity by Country
8.1.1 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2019-2024)
8.1.2 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2019-2024)
8.2 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)
8.3 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Liraglutide for The Treatment of Diabetes and Obesity
10.3 Manufacturing Process Analysis of Liraglutide for The Treatment of Diabetes and Obesity
10.4 Industry Chain Structure of Liraglutide for The Treatment of Diabetes and Obesity
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Liraglutide for The Treatment of Diabetes and Obesity Distributors
11.3 Liraglutide for The Treatment of Diabetes and Obesity Customer
12 WORLD FORECAST REVIEW FOR LIRAGLUTIDE FOR THE TREATMENT OF DIABETES AND OBESITY BY GEOGRAPHIC REGION
12.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Region
12.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Forecast by Region (2025-2030)
12.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Liraglutide for The Treatment of Diabetes and Obesity Forecast by Type (2025-2030)
12.7 Global Liraglutide for The Treatment of Diabetes and Obesity Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications
13.1.3 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 Teva
13.2.1 Teva Company Information
13.2.2 Teva Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications
13.2.3 Teva Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Teva Main Business Overview
13.2.5 Teva Latest Developments
13.3 Huadong Medicine
13.3.1 Huadong Medicine Company Information
13.3.2 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications
13.3.3 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Huadong Medicine Main Business Overview
13.3.5 Huadong Medicine Latest Developments
13.4 Sino Biopharm
13.4.1 Sino Biopharm Company Information
13.4.2 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications
13.4.3 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Sino Biopharm Main Business Overview
13.4.5 Sino Biopharm Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Liraglutide forTheTreatment of Diabetes and Obesity Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Liraglutide forTheTreatment of Diabetes and Obesity Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Original Drug
Table 4. Major Players of Generic Drug
Table 5. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)
Table 6. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)
Table 7. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue byType (2019-2024) & ($ million)
Table 8. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share byType (2019-2024)
Table 9. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Price byType (2019-2024) & (US$/Dose)
Table 10. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale by Application (2019-2024) & (K Dose)
Table 11. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Market Share by Application (2019-2024)
Table 12. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Application (2019-2024) & ($ million)
Table 13. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Application (2019-2024)
Table 14. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Price by Application (2019-2024) & (US$/Dose)
Table 15. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales by Company (2019-2024) & (K Dose)
Table 16. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Company (2019-2024)
Table 17. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Company (2019-2024)
Table 19. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Price by Company (2019-2024) & (US$/Dose)
Table 20. Key Manufacturers Liraglutide forTheTreatment of Diabetes and Obesity Producing Area Distribution and Sales Area
Table 21. Players Liraglutide forTheTreatment of Diabetes and Obesity Products Offered
Table 22. Liraglutide forTheTreatment of Diabetes and Obesity Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales by Geographic Region (2019-2024) & (K Dose)
Table 26. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share Geographic Region (2019-2024)
Table 27. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country/Region (2019-2024) & (K Dose)
Table 30. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country/Region (2019-2024)
Table 31. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country (2019-2024) & (K Dose)
Table 34. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country (2019-2024)
Table 35. Americas Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)
Table 37. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales by Application (2019-2024) & (K Dose)
Table 38. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales by Region (2019-2024) & (K Dose)
Table 39. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Region (2019-2024)
Table 40. APAC Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)
Table 42. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales by Application (2019-2024) & (K Dose)
Table 43. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country (2019-2024) & (K Dose)
Table 44. Europe Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)
Table 46. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales by Application (2019-2024) & (K Dose)
Table 47. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country (2019-2024) & (K Dose)
Table 48. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)
Table 50. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales by Application (2019-2024) & (K Dose)
Table 51. Key Market Drivers & Growth Opportunities of Liraglutide forTheTreatment of Diabetes and Obesity
Table 52. Key Market Challenges & Risks of Liraglutide forTheTreatment of Diabetes and Obesity
Table 53. Key IndustryTrends of Liraglutide forTheTreatment of Diabetes and Obesity
Table 54. Liraglutide forTheTreatment of Diabetes and Obesity Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Liraglutide forTheTreatment of Diabetes and Obesity Distributors List
Table 57. Liraglutide forTheTreatment of Diabetes and Obesity Customer List
Table 58. Global Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Region (2025-2030) & (K Dose)
Table 59. Global Liraglutide forTheTreatment of Diabetes and Obesity RevenueForecast by Region (2025-2030) & ($ millions)
Table 60. Americas Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Country (2025-2030) & (K Dose)
Table 61. Americas Liraglutide forTheTreatment of Diabetes and Obesity Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 62. APAC Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Region (2025-2030) & (K Dose)
Table 63. APAC Liraglutide forTheTreatment of Diabetes and Obesity Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 64. Europe Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Country (2025-2030) & (K Dose)
Table 65. Europe Liraglutide forTheTreatment of Diabetes and Obesity RevenueForecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Country (2025-2030) & (K Dose)
Table 67. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Global Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast byType (2025-2030) & (K Dose)
Table 69. Global Liraglutide forTheTreatment of Diabetes and Obesity RevenueForecast byType (2025-2030) & ($ millions)
Table 70. Global Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Application (2025-2030) & (K Dose)
Table 71. Global Liraglutide forTheTreatment of Diabetes and Obesity RevenueForecast by Application (2025-2030) & ($ millions)
Table 72. Novo Nordisk Basic Information, Liraglutide forTheTreatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors
Table 73. Novo Nordisk Liraglutide forTheTreatment of Diabetes and Obesity Product Portfolios and Specifications
Table 74. Novo Nordisk Liraglutide forTheTreatment of Diabetes and Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 75. Novo Nordisk Main Business
Table 76. Novo Nordisk Latest Developments
Table 77.Teva Basic Information, Liraglutide forTheTreatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors
Table 78.Teva Liraglutide forTheTreatment of Diabetes and Obesity Product Portfolios and Specifications
Table 79.Teva Liraglutide forTheTreatment of Diabetes and Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 80.Teva Main Business
Table 81.Teva Latest Developments
Table 82. Huadong Medicine Basic Information, Liraglutide forTheTreatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors
Table 83. Huadong Medicine Liraglutide forTheTreatment of Diabetes and Obesity Product Portfolios and Specifications
Table 84. Huadong Medicine Liraglutide forTheTreatment of Diabetes and Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 85. Huadong Medicine Main Business
Table 86. Huadong Medicine Latest Developments
Table 87. Sino Biopharm Basic Information, Liraglutide forTheTreatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors
Table 88. Sino Biopharm Liraglutide forTheTreatment of Diabetes and Obesity Product Portfolios and Specifications
Table 89. Sino Biopharm Liraglutide forTheTreatment of Diabetes and Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 90. Sino Biopharm Main Business
Table 91. Sino Biopharm Latest Developments
LIST OFFIGURES
Figure 1. Picture of Liraglutide forTheTreatment of Diabetes and Obesity
Figure 2. Liraglutide forTheTreatment of Diabetes and Obesity Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Liraglutide forTheTreatment of Diabetes and Obesity Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country/Region (2023)
Figure 10. Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Original Drug
Figure 12. Product Picture of Generic Drug
Figure 13. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType in 2023
Figure 14. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share byType (2019-2024)
Figure 15. Liraglutide forTheTreatment of Diabetes and Obesity Consumed in Hospital and Clinic
Figure 16. Global Liraglutide forTheTreatment of Diabetes and Obesity Market: Hospital and Clinic (2019-2024) & (K Dose)
Figure 17. Liraglutide forTheTreatment of Diabetes and Obesity Consumed in Retail Pharmacies
Figure 18. Global Liraglutide forTheTreatment of Diabetes and Obesity Market: Retail Pharmacies (2019-2024) & (K Dose)
Figure 19. Liraglutide forTheTreatment of Diabetes and Obesity Consumed in Other
Figure 20. Global Liraglutide forTheTreatment of Diabetes and Obesity Market: Other (2019-2024) & (K Dose)
Figure 21. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Market Share by Application (2023)
Figure 22. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Application in 2023
Figure 23. Liraglutide forTheTreatment of Diabetes and Obesity Sales by Company in 2023 (K Dose)
Figure 24. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Company in 2023
Figure 25. Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Company in 2023 ($ millions)
Figure 26. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Company in 2023
Figure 27. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)
Figure 30. Americas Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 ($ millions)
Figure 31. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)
Figure 32. APAC Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 ($ millions)
Figure 33. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)
Figure 34. Europe Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 ($ millions)
Figure 35. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)
Figure 36. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 ($ millions)
Figure 37. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country in 2023
Figure 38. Americas Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Country (2019-2024)
Figure 39. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)
Figure 40. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Application (2019-2024)
Figure 41. United States Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 42. Canada Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 43. Mexico Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 44. Brazil Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 45. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Region in 2023
Figure 46. APAC Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Region (2019-2024)
Figure 47. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)
Figure 48. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Application (2019-2024)
Figure 49. China Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 50. Japan Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 51. South Korea Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 52. Southeast Asia Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 53. India Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 54. Australia Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 55. ChinaTaiwan Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 56. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country in 2023
Figure 57. Europe Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Country (2019-2024)
Figure 58. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)
Figure 59. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Application (2019-2024)
Figure 60. Germany Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 61.France Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 62. UK Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 63. Italy Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 64. Russia Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 65. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country (2019-2024)
Figure 66. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)
Figure 67. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Application (2019-2024)
Figure 68. Egypt Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 69. South Africa Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 70. Israel Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 71.Turkey Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 72. GCC Countries Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Liraglutide forTheTreatment of Diabetes and Obesity in 2023
Figure 74. Manufacturing Process Analysis of Liraglutide forTheTreatment of Diabetes and Obesity
Figure 75. Industry Chain Structure of Liraglutide forTheTreatment of Diabetes and Obesity
Figure 76. Channels of Distribution
Figure 77. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales MarketForecast by Region (2025-2030)
Figure 78. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market ShareForecast by Region (2025-2030)
Figure 79. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market ShareForecast byType (2025-2030)
Figure 80. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market ShareForecast byType (2025-2030)
Figure 81. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market ShareForecast by Application (2025-2030)
Figure 82. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market ShareForecast by Application (2025-2030)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Liraglutide for The Treatment of Diabetes and Obesity by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Liraglutide for The Treatment of Diabetes and Obesity by Country/Region, 2019, 2023 & 2030
2.2 Liraglutide for The Treatment of Diabetes and Obesity Segment by Type
2.2.1 Original Drug
2.2.2 Generic Drug
2.3 Liraglutide for The Treatment of Diabetes and Obesity Sales by Type
2.3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Type (2019-2024)
2.3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue and Market Share by Type (2019-2024)
2.3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Price by Type (2019-2024)
2.4 Liraglutide for The Treatment of Diabetes and Obesity Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Liraglutide for The Treatment of Diabetes and Obesity Sales by Application
2.5.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Market Share by Application (2019-2024)
2.5.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue and Market Share by Application (2019-2024)
2.5.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Breakdown Data by Company
3.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales by Company (2019-2024)
3.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Company (2019-2024)
3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue by Company (2019-2024)
3.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Company (2019-2024)
3.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Company (2019-2024)
3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Price by Company
3.4 Key Manufacturers Liraglutide for The Treatment of Diabetes and Obesity Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Liraglutide for The Treatment of Diabetes and Obesity Product Location Distribution
3.4.2 Players Liraglutide for The Treatment of Diabetes and Obesity Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LIRAGLUTIDE FOR THE TREATMENT OF DIABETES AND OBESITY BY GEOGRAPHIC REGION
4.1 World Historic Liraglutide for The Treatment of Diabetes and Obesity Market Size by Geographic Region (2019-2024)
4.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country/Region (2019-2024)
4.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales by Country/Region (2019-2024)
4.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue by Country/Region (2019-2024)
4.3 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales Growth
4.4 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales Growth
4.5 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Growth
4.6 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Growth
5 AMERICAS
5.1 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Country
5.1.1 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2019-2024)
5.1.2 Americas Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2019-2024)
5.2 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)
5.3 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Region
6.1.1 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2019-2024)
6.1.2 APAC Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region (2019-2024)
6.2 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)
6.3 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Liraglutide for The Treatment of Diabetes and Obesity by Country
7.1.1 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2019-2024)
7.1.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2019-2024)
7.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)
7.3 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity by Country
8.1.1 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2019-2024)
8.1.2 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2019-2024)
8.2 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)
8.3 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Liraglutide for The Treatment of Diabetes and Obesity
10.3 Manufacturing Process Analysis of Liraglutide for The Treatment of Diabetes and Obesity
10.4 Industry Chain Structure of Liraglutide for The Treatment of Diabetes and Obesity
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Liraglutide for The Treatment of Diabetes and Obesity Distributors
11.3 Liraglutide for The Treatment of Diabetes and Obesity Customer
12 WORLD FORECAST REVIEW FOR LIRAGLUTIDE FOR THE TREATMENT OF DIABETES AND OBESITY BY GEOGRAPHIC REGION
12.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Region
12.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Forecast by Region (2025-2030)
12.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Liraglutide for The Treatment of Diabetes and Obesity Forecast by Type (2025-2030)
12.7 Global Liraglutide for The Treatment of Diabetes and Obesity Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications
13.1.3 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 Teva
13.2.1 Teva Company Information
13.2.2 Teva Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications
13.2.3 Teva Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Teva Main Business Overview
13.2.5 Teva Latest Developments
13.3 Huadong Medicine
13.3.1 Huadong Medicine Company Information
13.3.2 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications
13.3.3 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Huadong Medicine Main Business Overview
13.3.5 Huadong Medicine Latest Developments
13.4 Sino Biopharm
13.4.1 Sino Biopharm Company Information
13.4.2 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications
13.4.3 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Sino Biopharm Main Business Overview
13.4.5 Sino Biopharm Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Liraglutide forTheTreatment of Diabetes and Obesity Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Liraglutide forTheTreatment of Diabetes and Obesity Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Original Drug
Table 4. Major Players of Generic Drug
Table 5. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)
Table 6. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)
Table 7. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue byType (2019-2024) & ($ million)
Table 8. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share byType (2019-2024)
Table 9. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Price byType (2019-2024) & (US$/Dose)
Table 10. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale by Application (2019-2024) & (K Dose)
Table 11. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Market Share by Application (2019-2024)
Table 12. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Application (2019-2024) & ($ million)
Table 13. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Application (2019-2024)
Table 14. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Price by Application (2019-2024) & (US$/Dose)
Table 15. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales by Company (2019-2024) & (K Dose)
Table 16. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Company (2019-2024)
Table 17. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Company (2019-2024)
Table 19. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Price by Company (2019-2024) & (US$/Dose)
Table 20. Key Manufacturers Liraglutide forTheTreatment of Diabetes and Obesity Producing Area Distribution and Sales Area
Table 21. Players Liraglutide forTheTreatment of Diabetes and Obesity Products Offered
Table 22. Liraglutide forTheTreatment of Diabetes and Obesity Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales by Geographic Region (2019-2024) & (K Dose)
Table 26. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share Geographic Region (2019-2024)
Table 27. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country/Region (2019-2024) & (K Dose)
Table 30. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country/Region (2019-2024)
Table 31. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country (2019-2024) & (K Dose)
Table 34. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country (2019-2024)
Table 35. Americas Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)
Table 37. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales by Application (2019-2024) & (K Dose)
Table 38. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales by Region (2019-2024) & (K Dose)
Table 39. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Region (2019-2024)
Table 40. APAC Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)
Table 42. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales by Application (2019-2024) & (K Dose)
Table 43. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country (2019-2024) & (K Dose)
Table 44. Europe Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)
Table 46. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales by Application (2019-2024) & (K Dose)
Table 47. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country (2019-2024) & (K Dose)
Table 48. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)
Table 50. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales by Application (2019-2024) & (K Dose)
Table 51. Key Market Drivers & Growth Opportunities of Liraglutide forTheTreatment of Diabetes and Obesity
Table 52. Key Market Challenges & Risks of Liraglutide forTheTreatment of Diabetes and Obesity
Table 53. Key IndustryTrends of Liraglutide forTheTreatment of Diabetes and Obesity
Table 54. Liraglutide forTheTreatment of Diabetes and Obesity Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Liraglutide forTheTreatment of Diabetes and Obesity Distributors List
Table 57. Liraglutide forTheTreatment of Diabetes and Obesity Customer List
Table 58. Global Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Region (2025-2030) & (K Dose)
Table 59. Global Liraglutide forTheTreatment of Diabetes and Obesity RevenueForecast by Region (2025-2030) & ($ millions)
Table 60. Americas Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Country (2025-2030) & (K Dose)
Table 61. Americas Liraglutide forTheTreatment of Diabetes and Obesity Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 62. APAC Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Region (2025-2030) & (K Dose)
Table 63. APAC Liraglutide forTheTreatment of Diabetes and Obesity Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 64. Europe Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Country (2025-2030) & (K Dose)
Table 65. Europe Liraglutide forTheTreatment of Diabetes and Obesity RevenueForecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Country (2025-2030) & (K Dose)
Table 67. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Global Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast byType (2025-2030) & (K Dose)
Table 69. Global Liraglutide forTheTreatment of Diabetes and Obesity RevenueForecast byType (2025-2030) & ($ millions)
Table 70. Global Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Application (2025-2030) & (K Dose)
Table 71. Global Liraglutide forTheTreatment of Diabetes and Obesity RevenueForecast by Application (2025-2030) & ($ millions)
Table 72. Novo Nordisk Basic Information, Liraglutide forTheTreatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors
Table 73. Novo Nordisk Liraglutide forTheTreatment of Diabetes and Obesity Product Portfolios and Specifications
Table 74. Novo Nordisk Liraglutide forTheTreatment of Diabetes and Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 75. Novo Nordisk Main Business
Table 76. Novo Nordisk Latest Developments
Table 77.Teva Basic Information, Liraglutide forTheTreatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors
Table 78.Teva Liraglutide forTheTreatment of Diabetes and Obesity Product Portfolios and Specifications
Table 79.Teva Liraglutide forTheTreatment of Diabetes and Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 80.Teva Main Business
Table 81.Teva Latest Developments
Table 82. Huadong Medicine Basic Information, Liraglutide forTheTreatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors
Table 83. Huadong Medicine Liraglutide forTheTreatment of Diabetes and Obesity Product Portfolios and Specifications
Table 84. Huadong Medicine Liraglutide forTheTreatment of Diabetes and Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 85. Huadong Medicine Main Business
Table 86. Huadong Medicine Latest Developments
Table 87. Sino Biopharm Basic Information, Liraglutide forTheTreatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors
Table 88. Sino Biopharm Liraglutide forTheTreatment of Diabetes and Obesity Product Portfolios and Specifications
Table 89. Sino Biopharm Liraglutide forTheTreatment of Diabetes and Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 90. Sino Biopharm Main Business
Table 91. Sino Biopharm Latest Developments
LIST OFFIGURES
Figure 1. Picture of Liraglutide forTheTreatment of Diabetes and Obesity
Figure 2. Liraglutide forTheTreatment of Diabetes and Obesity Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Liraglutide forTheTreatment of Diabetes and Obesity Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country/Region (2023)
Figure 10. Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Original Drug
Figure 12. Product Picture of Generic Drug
Figure 13. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType in 2023
Figure 14. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share byType (2019-2024)
Figure 15. Liraglutide forTheTreatment of Diabetes and Obesity Consumed in Hospital and Clinic
Figure 16. Global Liraglutide forTheTreatment of Diabetes and Obesity Market: Hospital and Clinic (2019-2024) & (K Dose)
Figure 17. Liraglutide forTheTreatment of Diabetes and Obesity Consumed in Retail Pharmacies
Figure 18. Global Liraglutide forTheTreatment of Diabetes and Obesity Market: Retail Pharmacies (2019-2024) & (K Dose)
Figure 19. Liraglutide forTheTreatment of Diabetes and Obesity Consumed in Other
Figure 20. Global Liraglutide forTheTreatment of Diabetes and Obesity Market: Other (2019-2024) & (K Dose)
Figure 21. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Market Share by Application (2023)
Figure 22. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Application in 2023
Figure 23. Liraglutide forTheTreatment of Diabetes and Obesity Sales by Company in 2023 (K Dose)
Figure 24. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Company in 2023
Figure 25. Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Company in 2023 ($ millions)
Figure 26. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Company in 2023
Figure 27. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)
Figure 30. Americas Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 ($ millions)
Figure 31. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)
Figure 32. APAC Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 ($ millions)
Figure 33. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)
Figure 34. Europe Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 ($ millions)
Figure 35. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)
Figure 36. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 ($ millions)
Figure 37. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country in 2023
Figure 38. Americas Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Country (2019-2024)
Figure 39. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)
Figure 40. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Application (2019-2024)
Figure 41. United States Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 42. Canada Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 43. Mexico Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 44. Brazil Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 45. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Region in 2023
Figure 46. APAC Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Region (2019-2024)
Figure 47. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)
Figure 48. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Application (2019-2024)
Figure 49. China Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 50. Japan Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 51. South Korea Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 52. Southeast Asia Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 53. India Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 54. Australia Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 55. ChinaTaiwan Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 56. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country in 2023
Figure 57. Europe Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Country (2019-2024)
Figure 58. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)
Figure 59. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Application (2019-2024)
Figure 60. Germany Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 61.France Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 62. UK Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 63. Italy Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 64. Russia Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 65. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country (2019-2024)
Figure 66. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)
Figure 67. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Application (2019-2024)
Figure 68. Egypt Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 69. South Africa Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 70. Israel Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 71.Turkey Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 72. GCC Countries Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Liraglutide forTheTreatment of Diabetes and Obesity in 2023
Figure 74. Manufacturing Process Analysis of Liraglutide forTheTreatment of Diabetes and Obesity
Figure 75. Industry Chain Structure of Liraglutide forTheTreatment of Diabetes and Obesity
Figure 76. Channels of Distribution
Figure 77. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales MarketForecast by Region (2025-2030)
Figure 78. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market ShareForecast by Region (2025-2030)
Figure 79. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market ShareForecast byType (2025-2030)
Figure 80. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market ShareForecast byType (2025-2030)
Figure 81. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market ShareForecast by Application (2025-2030)
Figure 82. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market ShareForecast by Application (2025-2030)
